Skip to main content

Table 1 Demographics for all treated patients as well as those completing treatment

From: A phase 1/2, open-label assessment of the safety, tolerability, and efficacy of transdermal cannabidiol (ZYN002) for the treatment of pediatric fragile X syndrome

 

All treated patients (N = 20)

Patients completing week 12 (N = 18)

Age (years): mean (SD)

10.40 (3.88)

10.78 (3.86)

 Range (min, max)

6–17

6–17

BMI (kg/m2): mean (SD)

19.34 (5.75)

19.50 (5.97)

 Range (min, max)

12.60–35.00

12.60–35.00

Sex: frequency (%)

 Male

15 (75.00%)

14 (77.80%)

 Female

5 (25.00%)

4 (22.20%)

Ethnicity: frequency (%)

 White, not Hispanic or Latino

18 (90.00%)

16 (88.90%)

 Other (Middle Eastern)

2 (10.00%)

2 (11.10%)